Pure Global

Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes - Trial NCT06334133

Access comprehensive clinical trial information for NCT06334133 through Pure Global AI's free database. This Phase 3 trial is sponsored by vTv Therapeutics and is currently Not yet recruiting. The study focuses on Diabetes Mellitus, Type 1. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06334133
Phase 3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06334133
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes
Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 52-Week Double-Blind, Randomized, Placebo-Controlled Phase 3 Study

Study Focus

Diabetes Mellitus, Type 1

Cadisegliatin 800 mg QD

Interventional

drug

Sponsor & Location

vTv Therapeutics

Timeline & Enrollment

Phase 3

May 01, 2024

Mar 01, 2026

150 participants

Primary Outcome

Change in incidence of Level 2 or Level 3 hypoglycemia

Summary

This is a Phase 3 trial of cadisegliatin in participants with Type 1 Diabetes Mellitus.

ICD-10 Classifications

Type 1 diabetes mellitus
Type 1 diabetes mellitus with unspecified complications
Type 1 diabetes mellitus with other specified complications
Type 1 diabetes mellitus without complications
Type 1 diabetes mellitus with multiple complications

Data Source

ClinicalTrials.gov

NCT06334133

Non-Device Trial